Zhejiang East Asia Pharmaceutical Co., Ltd.

SHSE:605177 Stock Report

Market Cap: CN¥2.1b

Zhejiang East Asia Pharmaceutical Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Cheng Chi

Chief executive officer

CN¥1.3m

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership6.9%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Zhejiang East Asia Pharmaceutical's (SHSE:605177) Shareholders Have More To Worry About Than Only Soft Earnings

Nov 06
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Shareholders Have More To Worry About Than Only Soft Earnings

Zhejiang East Asia Pharmaceutical Co., Ltd.'s (SHSE:605177) Shares Lagging The Market But So Is The Business

Oct 02
Zhejiang East Asia Pharmaceutical Co., Ltd.'s (SHSE:605177) Shares Lagging The Market But So Is The Business

Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals

May 06
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals

Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Apr 23
Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Take Care Before Diving Into The Deep End On Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177)

Feb 28
Take Care Before Diving Into The Deep End On Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177)

CEO

Cheng Chi (40 yo)

no data

Tenure

CN¥1,304,900

Compensation

Mr. Cheng Chi serves as Director and General Manager at Zhejiang East Asia Pharmaceutical Co., Ltd. and served as its Deputy Manager.